Clinical Trials Logo

Adult Anaplastic Astrocytoma clinical trials

View clinical trials related to Adult Anaplastic Astrocytoma.

Filter by:

NCT ID: NCT00499473 Completed - Adult Glioblastoma Clinical Trials

Sunitinib in Treating Patients With Recurrent Malignant Gliomas

Start date: June 2007
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well sunitinib works in treating patients with recurrent malignant gliomas. Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

NCT ID: NCT00492089 Completed - Malignant Neoplasm Clinical Trials

Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer

Start date: June 2007
Phase: Phase 2
Study type: Interventional

Bevacizumab may reduce CNS side effects caused by radiation therapy. This randomized phase II trial is studying how well bevacizumab works in reducing CNS side effects in patients who have undergone radiation therapy to the brain for primary brain tumor, meningioma, or head and neck cancer.

NCT ID: NCT00369590 Completed - Adult Gliosarcoma Clinical Trials

VEGF Trap in Treating Patients With Recurrent Malignant Gliomas That Did Not Respond to Temozolomide

Start date: August 2006
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well VEGF Trap works in treating patients with recurrent malignant or anaplastic gliomas that did not respond to temozolomide. VEGF Trap may stop the growth of malignant or anaplastic gliomas by blocking blood flow to the tumor.

NCT ID: NCT00112736 Completed - Adult Glioblastoma Clinical Trials

Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma

Start date: April 2005
Phase: Phase 1/Phase 2
Study type: Interventional

Erlotinib and temsirolimus and may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. This phase I/II trial is studying the side effects and best dose of temsirolimus when given together with erlotinib and to see how well they work in treating patients with recurrent malignant glioma.

NCT ID: NCT00093613 Completed - Adult Gliosarcoma Clinical Trials

Sorafenib in Treating Patients With Recurrent or Progressive Malignant Glioma

Start date: December 2004
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the side effects and best dose of sorafenib in treating patients with recurrent or progressive malignant glioma. Sorafenib may stop the growth of tumor cells by stopping blood flow to the tumor and by blocking the enzymes necessary for their growth.

NCT ID: NCT00085540 Completed - Adult Gliosarcoma Clinical Trials

FR901228 in Treating Patients With Recurrent High-Grade Gliomas

Start date: January 2005
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial is studying the side effects and best dose of FR901228 and to see how well it works in treating patients with recurrent high-grade gliomas. FR901228 may stop the growth of tumor cells by blocking the enzymes necessary for their growth

NCT ID: NCT00045708 Completed - Adult Gliosarcoma Clinical Trials

A Phase I/II Trial of BMS-247550 for Treatment of Patients With Recurrent High-Grade Gliomas

Start date: October 2002
Phase: Phase 1/Phase 2
Study type: Interventional

Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. This phase I/II trial is studying the side effects and best dose of ixabepilone and how well it works in treating patients with recurrent glioma.

NCT ID: NCT00030498 Completed - Clinical trials for Unspecified Adult Solid Tumor, Protocol Specific

Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction

Start date: December 2001
Phase: Phase 1
Study type: Interventional

Phase I trial to study the effectiveness of erlotinib in treating patients who have metastatic or unresectable solid tumors and liver or kidney dysfunction. Biological therapies such as erlotinib may interfere with the growth of tumor cells and slow the growth of the tumor